Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.

Ethereum’s Fusaka upgrade introduces PeerDAS, new blob economics and key UX improvements that push deeper into the Surge, ...

The HackerEarth platform itself is pretty standard for online coding tests. You’ll have a code editor where you write your ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Etien Yovchev is the co-founder and managing partner of The Recursive, a tech media covering trends in Europe's AI economy.

These are some of the fastest, biggest gains I’ve seen in my career.  But they were just the appetizer.  The main course? The Genesis Mission – the single most important investment theme of ...

Infectious diseases such as bacterial, viral, fungal and parasitic diseases continue to have a significant impact on global health. Hence, knowledge on how infection spread, population vulnerable to ...

Recursive Agents implements a three-phase iterative refinement architecture where LLM agents (instances of Classes) critique and improve their own outputs. Unlike single-pass systems, each agent ...

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed.